Jinxin Fertility Group Limited (JXFGF)
Jinxin Fertility Group Limited operates in the Medical - Care Facilities industry of the Healthcare sector, headquartered in Chengdu, SI, CN. The stock last traded at $0.29, up 0.00% on the session, giving a market capitalisation of $740.3M. On trailing twelve-month figures it carries a trailing P/E of -5.08, a net margin of -37.2%. Its beta of 0.77 implies it has historically moved less than the broad market.
Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company primarily focused on delivering assisted reproductive services (ARS) across both China and the United States. The company offers a comprehensive range of fertility treatments, encompassing artificial insemination, which can be performed using either a husband's or donor sperm, and advanced in vitro fertilization (IVF) techniques such as conventional IVF with embryo transfer or IVF enhanced by intracytoplasmic sperm injection (ICSI). Supporting these core services, Jinxin also provides patients with nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, its operations extend to general medical services including gynecology, urology, and internal medicine, along with managing outpatient surgical facilities and various ancillary medical provisions. The group also conducts pre-implantation genetic screening tests and engages in diverse ventures like investment management, management consultancy, and real estate development and operation.
Jinxin Fertility Group Limited is most often compared with the following Healthcare names: